Our experience with COVID-19 related Mucormycosis: a preliminary report

Abstract

India has seen, much to its dismay, a massive and baffling surge of Mucormycosis in association with COVID19. It has been a challenging, distressing, disappointing and frustrating experience during the second wave. We have seen it during the illness, but more in the postrecovery phase. It is known to occur in patients with lowered immunity postCOVID, uncontrolled diabetes, posttransplant, post-cancer treatments, hematological disorders and AIDS. This was generally considered rather rare until the status dramatically changed recently. Geographically south east Asia has recorded a good number of cases. Infection with Mucormycosis has high morbidity and mortality rate, can cause loss of eye and may be life threatening due to the invasive nature of the fungal infection which can present as Rhinocerebral Mucor. This disease requires immediate attention and a tailored treatment plan to achieve full recovery without loss of function.